Home/ Stocks/ REGN

Regeneron Pharmaceuticals Inc

REGN XNAS

$902.90 -33.77 (-3.63%) ▼ 15-min delayed

Open

$938.51

High

$948.11

Low

$901.53

Volume

1.42M

Market Cap

$96.28B

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 15.4K Website →

Earnings & Analyst Ratings

Next Earnings: Thu, Jan 28, 2027

Calendar →

TickerDaily Coverage

Top Pre-Market Movers Today: 5 Stocks Making Biggest Moves Before the Bell

Market News Sarah Mitchell · Aug 27, 2026

Five major stocks are making significant pre-market moves Thursday morning before the opening bell....

Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)

Market News David Brooks · Jul 3, 2026

The healthcare sector capped a record-breaking first half with a strong week as XLV rallied on...

Top Stocks Moving Pre-Market Today: NVDA, LLY, AMD Pre-Market Movers Before the Bell

Market News Sarah Mitchell · Mar 6, 2026

Several major stocks are posting outsized pre-market moves ahead of today's opening bell, driven by...

View All Coverage →

Get REGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Regeneron Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.